Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

calbucs Apr. 29 at 2:13 PM

$NKTR Frustrading to see shorts have their way time and time again . Took us months to get to $109 and they take it down in a week ! $92 raise and we are under $10 from there . We are here for the Win !! It’s coming , LLY Will settle and pay up . Once approved watch out above !

1 · Reply

mreitnour Apr. 29 at 2:11 PM

$NKTR Congrats to the shorts on an impressive beat down.

0 · Reply

paleogos Apr. 29 at 12:06 PM

$NKTR Knife still hot

0 · Reply

mreitnour Apr. 28 at 7:33 PM

$NKTR Brutal. Like a hot knife through butter. Doesn’t appear to be any abating of the selling.

1 · Reply

george4it Apr. 28 at 6:02 PM

$NKTR Me thinks this returns to 91 very soon, just like the last time.

0 · Reply

george4it Apr. 28 at 5:57 PM

$NKTR Added more. Call me crazy.

0 · Reply

calbucs Apr. 28 at 4:51 PM

$NKTR Yeah , This is way over done !! With several big name funds into this at $92 a share , one would think they should not be able to continue this , need a bounce now .

1 · Reply

lilBobbyBagholder Apr. 28 at 4:07 PM

$NKTR Is the Adam May MD pump sputtering out?

1 · Reply

george4it Apr. 28 at 3:05 PM

$NKTR $COHR $ALAB I added heavily in these names today.

0 · Reply

mreitnour Apr. 28 at 2:56 PM

$NKTR This is interesting. Offering at $92, and it has fallen precipitously through that level. Where is the support?

1 · Reply

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

Apr 28, 2026, 4:09 PM EDT - 19 hours ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR

Apr 28, 2026, 9:00 AM EDT - 1 day ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR

Apr 23, 2026, 4:15 PM EDT - 5 days ago

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 21, 2026, 9:30 PM EDT - 7 days ago

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

Apr 20, 2026, 4:01 PM EDT - 8 days ago

Nektar Therapeutics Announces Proposed Public Offering

Apr 20, 2026, 11:43 AM EDT - 8 days ago

This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.

Apr 20, 2026, 9:16 AM EDT - 9 days ago

Why Are Nektar Shares Up Monday?

Apr 20, 2026, 8:00 AM EDT - 9 days ago

Nektar Therapeutics Transcript: Study update

Apr 20, 2026, 7:30 AM EDT - 9 days ago

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

Apr 19, 2026, 12:00 PM EDT - 9 days ago

Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

Apr 9, 2026, 8:23 AM EDT - 20 days ago

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

Mar 31, 2026, 2:50 PM EDT - 4 weeks ago

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

Mar 28, 2026, 12:36 PM EDT - 4 weeks ago

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Mar 20, 2026, 10:00 AM EDT - 5 weeks ago

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

Mar 12, 2026, 5:00 PM EDT - 6 weeks ago

Nektar Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:15 PM EDT - 6 weeks ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 5:58 PM EDT - 7 weeks ago

NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Mar 9, 2026, 7:10 AM EDT - 7 weeks ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)

Mar 6, 2026, 6:00 PM EST - 7 weeks ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2026, 9:10 AM EST - 2 months ago

Nektar Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:00 PM EST - 2 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

Feb 24, 2026, 6:00 PM EST - 2 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in March

Feb 17, 2026, 7:00 AM EST - 2 months ago

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

Feb 13, 2026, 4:15 PM EST - 2 months ago

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 13, 2026, 9:30 AM EST - 2 months ago

Can NKTR Stock Sustain Its 1,000% Rally?

Feb 11, 2026, 10:23 PM EST - 2 months ago

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

Feb 11, 2026, 7:35 AM EST - 2 months ago

Why Is Nektar Therapeutics Stock Gaining Wednesday?

Feb 10, 2026, 8:00 AM EST - 2 months ago

Nektar Therapeutics Transcript: Study result

Feb 10, 2026, 7:00 AM EST - 2 months ago

New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

Feb 9, 2026, 4:15 PM EST - 2 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Jan 15, 2026, 6:58 PM EST - 3 months ago

Nektar.io Introduces DIRT: Materials Management for the Construction Industry

Dec 16, 2025, 11:30 AM EST - 4 months ago

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Dec 16, 2025, 8:00 AM EST - 4 months ago

Nektar Therapeutics Transcript: Study Result

Dec 15, 2025, 6:00 PM EST - 4 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Nov 20, 2025, 6:00 AM EST - 5 months ago

Nektar Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 8, 2025, 5:45 PM EST - 6 months ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 6, 2025, 5:00 PM EST - 6 months ago

Nektar Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:15 PM EST - 6 months ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 6 months ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 6 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 6 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 2:31 PM EDT - 7 months ago

Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Sep 18, 2025, 8:45 AM EDT - 7 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 15, 2025, 2:30 PM EDT - 8 months ago

Nektar Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:30 AM EDT - 8 months ago

Nektar Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:00 AM EDT - 8 months ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 4, 2025, 2:52 PM EDT - 8 months ago

What's Going On With Nektar Therapeutics Stock On Thursday?

Sep 3, 2025, 7:00 PM EDT - 8 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 9 months ago

Nektar Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:15 PM EDT - 9 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 9 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 9 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 10 months ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 10 months ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 24, 2025, 8:15 AM EDT - 11 months ago

Nektar Therapeutics Transcript: Study Update

May 20, 2025, 1:30 PM EDT - 1 year ago

Nektar Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Nektar Therapeutics Earnings Call Transcript: Q1 2025

Mar 27, 2025, 2:00 PM EDT - 1 year ago

Nektar Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 5:00 PM EDT - 1 year ago

Nektar Therapeutics Earnings Call Transcript: Q4 2024

Feb 24, 2025, 3:00 PM EST - 1 year ago

Nektar Therapeutics Transcript: Study Update

Dec 4, 2024, 1:00 PM EST - 1 year ago

Nektar Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 1:15 PM EST - 1 year ago

Nektar Therapeutics Transcript: UBS Global Healthcare Conference 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Nektar Therapeutics Earnings Call Transcript: Q3 2024

Sep 17, 2024, 12:30 PM EDT - 1 year ago

Nektar Therapeutics Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Sep 9, 2024, 3:00 PM EDT - 1 year ago

Nektar Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Nektar Therapeutics Earnings Call Transcript: Q2 2024

Jun 10, 2024, 2:00 PM EDT - 2 years ago

Nektar Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 3:30 PM EDT - 2 years ago

Nektar Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 9, 2024, 5:00 PM EDT - 2 years ago

Nektar Therapeutics Earnings Call Transcript: Q1 2024

Mar 28, 2024, 1:30 PM EDT - 2 years ago

Nektar Therapeutics Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference 2024

Mar 5, 2024, 2:10 PM EST - 2 years ago

Nektar Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 5:00 PM EST - 2 years ago

Nektar Therapeutics Earnings Call Transcript: Q4 2023

Jan 10, 2024, 8:15 PM EST - 2 years ago

Nektar Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 7, 2023, 5:00 PM EST - 2 years ago

Nektar Therapeutics Earnings Call Transcript: Q3 2023

Sep 13, 2023, 11:00 AM EDT - 2 years ago

Nektar Therapeutics Transcript: Status Update

Aug 8, 2023, 5:00 PM EDT - 2 years ago

Nektar Therapeutics Earnings Call Transcript: Q2 2023

May 9, 2023, 5:00 PM EDT - 3 years ago

Nektar Therapeutics Earnings Call Transcript: Q1 2023

calbucs Apr. 29 at 2:13 PM

1 · Reply

mreitnour Apr. 29 at 2:11 PM

$NKTR Congrats to the shorts on an impressive beat down.

0 · Reply

paleogos Apr. 29 at 12:06 PM

$NKTR Knife still hot

0 · Reply

mreitnour Apr. 28 at 7:33 PM

$NKTR Brutal. Like a hot knife through butter. Doesn’t appear to be any abating of the selling.

1 · Reply

george4it Apr. 28 at 6:02 PM

$NKTR Me thinks this returns to 91 very soon, just like the last time.

0 · Reply

george4it Apr. 28 at 5:57 PM

$NKTR Added more. Call me crazy.

0 · Reply

calbucs Apr. 28 at 4:51 PM

$NKTR Yeah , This is way over done !! With several big name funds into this at $92 a share , one would think they should not be able to continue this , need a bounce now .

1 · Reply

lilBobbyBagholder Apr. 28 at 4:07 PM

$NKTR Is the Adam May MD pump sputtering out?

1 · Reply

george4it Apr. 28 at 3:05 PM

$NKTR $COHR $ALAB I added heavily in these names today.

0 · Reply

mreitnour Apr. 28 at 2:56 PM

$NKTR This is interesting. Offering at $92, and it has fallen precipitously through that level. Where is the support?

1 · Reply

Pihedgy Apr. 28 at 2:00 PM

$NKTR weak bounce. $76 here we come.

2 · Reply

FlyingTargets Apr. 27 at 8:03 PM

$SNDX $NKTR Sm

0 · Reply

mreitnour Apr. 27 at 7:50 PM

$NKTR This is ridiculous.

0 · Reply

george4it Apr. 27 at 7:20 PM

$NKTR Is that gap finally closed or what?

2 · Reply

george4it Apr. 27 at 7:18 PM

$NKTR Added.

0 · Reply

iwtd Apr. 27 at 7:13 PM

$NKTR Household costs will increase because of increasing global oil and gas prices, which would likely raise energy bills, food costs, and air fares. Consumers could feel the financial impact for many months through broader inflation and higher living costs. What does this mean? Let's find out. https://youtu.be/kQk3B_TGfwU

0 · Reply

autographic Apr. 27 at 6:45 PM

🚨 $NKTR pulled back to support line. Added some .

0 · Reply

calbucs Apr. 27 at 6:10 PM

$NKTR A bit surpricing they are allowing the shorts to walk this down below the last offering of $92 a share ? , I expected us to resume upward movement to at least $100 to $110 . With 33.7 Million shares outstanding , it can move Back up quickly , look at The swing today from $94 to $87 , let’s reverse !! Crooked Short spewing their BS and attacking right now .

0 · Reply

george4it Apr. 27 at 6:07 PM

$NKTR I feel another few hundred add to my portfolio might be coming.

0 · Reply

ShortESPR Apr. 27 at 5:40 PM

$NKTR They might be diluting via ATM. I heard their CEO has no clue

2 · Reply

Lucky72 Apr. 27 at 1:25 PM

$NKTR Congratulations Everyone,I 🏦 to soon.

0 · Reply

calbucs Apr. 27 at 12:50 PM

$NKTR Analyst PT’s have been raised aggressively and institutional buying has revved up ! Almost 80% owned by institutional investors !! Hedge funds and other institutional investors have recently modified their holdings of the company. Pictet Asset Management Holding SA purchased a new position in shares of Nektar Therapeutics in the first quarter valued at $268,000. OP Asset Management Ltd bought a new position in Nektar Therapeutics during the first quarter valued at $287,000. Seven Fleet Capital Management LP bought a new position in Nektar Therapeutics during the fourth quarter valued at $634,000. Virtu Financial LLC purchased a new position in shares of Nektar Therapeutics in the 4th quarter worth $584,000. Finally, Invesco Ltd. increased its holdings in shares of Nektar Therapeutics by 106.3% in the 4th quarter. Invesco Ltd. now owns 468,159 shares of the biopharmaceutical company's stock worth $19,794,000 after buying an additional 241,262 shares during the last quarter.

0 · Reply

Market Cap	2.72B
Revenue (ttm)	55.23M
Net Income (ttm)	-164.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-297.08%
Debt to Equity Ratio	0.00

Volume	1,198,500
Avg Vol	1,077,980
Day's Range	N/A - N/A
Shares Out	29.68M
Stochastic %K	12%
Beta	1.16
Analysts	Strong Sell
Price Target	$144.25